Real‐world evidence of the safety and survival with CD19 CAR‐T cell therapy for relapsed/refractory solid organ transplant‐related PTLD

Overview of attention for article published in British Journal of Haematology, May 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

twitter: 54 X users

Readers on

mendeley: 50 Mendeley

So far, Altmetric has seen 63 X posts from 54 X users, with an upper bound of 135,305 followers.

@ReshmaRamlal2 @NitinJainMD @DrMarcosdelima @HayderSaeed_MD @TaniaJain11 @GvHD_Meade We published our overall feasible and successful series -so yes https://t.co/SXgSutKp6G https://t.co/7b0dCikNUm

Real‐world evidence of the safety and survival with CD19 CAR‐T cell therapy for relapsed/refractory solid organ transplant‐related PTLD - McKenna - 2023 - British Journal of Haematology - Wiley Online Library https://t.co/c7agPb8e27

Options for relapsed PTLD Worth adding @DrAEvens @sairah__ahmed et al’s recent @BrJHaem series of CD19 CAR T-cell treated pts with PTLD https://t.co/RdycDDZR0t #17ICML #PTLD #lymsm https://t.co/Do7ttT5HZO

RT @BrJHaem: Real-World Evidence: CD19 CAR-T therapy in SOT-related PTLD w/ similar response rates & toxicity rates c/w previously reported…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 59 additional X posts.